Qlife Holding Gestion

Gestion contrôle des critères 1/4

Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.

Informations clés

Thomas Warthoe

Directeur général

SEK 1.9m

Rémunération totale

Pourcentage du salaire du PDG	98.9%
Durée du mandat du directeur général	4.8yrs
Propriété du PDG	0.03%
Durée moyenne d'occupation des postes de direction	pas de données
Durée moyenne du mandat des membres du conseil d'administration	2.4yrs

Mises à jour récentes de la gestion

Shareholders May Be A Bit More Conservative With Qlife Holding AB (publ)'s (STO:QLIFE) CEO Compensation For Now

Jun 19

Recent updates

Shareholders May Be A Bit More Conservative With Qlife Holding AB (publ)'s (STO:QLIFE) CEO Compensation For Now

Jun 19

Is Qlife Holding (STO:QLIFE) A Risky Investment?

Aug 05

Is Qlife Holding (STO:QLIFE) A Risky Investment?

Feb 23

Analyse de la rémunération des PDG

Comment la rémunération de Thomas Warthoe a-t-elle évolué par rapport aux bénéfices de Qlife Holding?
Date	Rémunération totale	Salaire	Bénéfices de l'entreprise
Sep 30 2024	n/a	n/a	-SEK 161m
Jun 30 2024	n/a	n/a	-SEK 142m
Mar 31 2024	n/a	n/a	-SEK 152m
Dec 31 2023	SEK 2m	SEK 2m	-SEK 160m
Sep 30 2023	n/a	n/a	-SEK 85m
Jun 30 2023	n/a	n/a	-SEK 97m
Mar 31 2023	n/a	n/a	-SEK 95m
Dec 31 2022	SEK 2m	SEK 2m	-SEK 93m
Sep 30 2022	n/a	n/a	-SEK 69m
Jun 30 2022	n/a	n/a	-SEK 62m
Mar 31 2022	n/a	n/a	-SEK 60m
Dec 31 2021	SEK 2m	SEK 2m	-SEK 39m
Sep 30 2021	n/a	n/a	-SEK 33m
Jun 30 2021	n/a	n/a	-SEK 23m
Mar 31 2021	n/a	n/a	-SEK 15m
Dec 31 2020	SEK 1m	n/a	-SEK 20m
Sep 30 2020	n/a	n/a	-SEK 37m
Jun 30 2020	n/a	n/a	-SEK 37m
Mar 31 2020	n/a	n/a	-SEK 38m
Dec 31 2019	SEK 1m	n/a	-SEK 32m

Rémunération vs marché: La rémunération totale de Thomas ($USD 171.01K ) est dans la moyenne des entreprises de taille similaire sur le marché Swedish ($USD 236.52K ).

Rémunération et revenus: La rémunération de Thomas a augmenté alors que l'entreprise n'est pas rentable.

PDG

Thomas Warthoe (57 yo)

4.8yrs

Titularisation

SEK 1,881,000

Compensation

Mr. Thomas Warthoe founded Atonomics A/S in 2000 and also serves as its Chief Executive Officer. He is a Co-Founder of Qlife Holding AB (publ) and serves as it's Chief Executive Officer. He has been a Dire...

Membres du conseil d'administration

Nom	Position	Titularisation	Compensation	Propriété
Thomas Warthoe	Co-Founder	4.8yrs	SEK 1.88m	0.030% SEK 2.1k
Lars Bangsgaard	Independent Chairman	1.8yrs	SEK 175.00k	0.024% SEK 1.7k
Mikael Persson	Independent Director	3.5yrs	SEK 107.00k	0.012% SEK 861.1
Lars Wegner	Independent Director	1.8yrs	SEK 88.00k	pas de données
Jan Lisby	Member of Scientific Advisory Board	2.4yrs	pas de données	pas de données

2.4yrs

Durée moyenne de l'emploi

57yo

Âge moyen

Conseil d'administration expérimenté: Le conseil d'administration de la QLIFE n'est pas considéré comme expérimenté ( 2.4 années d'ancienneté moyenne), ce qui suggère un nouveau conseil d'administration.

Qlife Holding Gestion

Gestion contrôle des critères 1/4

Informations clés

Mises à jour récentes de la gestion

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

Shareholders May Be A Bit More Conservative With Qlife Holding AB (publ)'s (STO:QLIFE) CEO Compensation For Now

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: kr0.006 loss per share (vs kr27.66 loss in 3Q 2023)

Qlife Holding AB (publ) Announces Peter Warthoe Will Return to the Management Group as Chief Scientific Officer

Second quarter 2024 earnings released: kr0.006 loss per share (vs kr98.15 loss in 2Q 2023)

Qlife Participates Research Trial for People Living with PKU and Gets Positive Data

Shareholders May Be A Bit More Conservative With Qlife Holding AB (publ)'s (STO:QLIFE) CEO Compensation For Now

Qlife Starts Clinical Trial in China with First Biomarker on Egoo Health

New major risk - Shareholder dilution

Qlife Holding AB (publ) to Report Q2, 2024 Results on Aug 15, 2024

First quarter 2024 earnings released: kr0.013 loss per share (vs kr0.081 loss in 1Q 2023)

Qlife Holding AB (publ) has completed a Composite Units Offering in the amount of SEK 30.150028 million.

Full year 2023 earnings released: kr0.42 loss per share (vs kr5.46 loss in FY 2022)

New major risk - Financial position

Qlife Holding AB (publ) to Report Fiscal Year 2023 Results on Feb 05, 2024

Third quarter 2023 earnings released: kr0.014 loss per share (vs kr1.34 loss in 3Q 2022)

New major risk - Shareholder dilution

New major risk - Revenue size

Second quarter 2023 earnings released: kr0.049 loss per share (vs kr1.30 loss in 2Q 2022)

Qlife Holding AB (publ) announced that it has received SEK 4.647035 million in funding from Pensys Ab, Jinderman & Partners AB

High number of new and inexperienced directors

Full year 2022 earnings released: kr5.46 loss per share (vs kr3.04 loss in FY 2021)

Full year 2022 earnings released: kr4.93 loss per share (vs kr3.83 loss in FY 2021)

Third quarter 2022 earnings released: kr1.34 loss per share (vs kr1.10 loss in 3Q 2021)

Qlife Holding AB (publ) to Report Q3, 2023 Results on Nov 02, 2023

High number of new and inexperienced directors

Second quarter 2022 earnings released: kr1.30 loss per share (vs kr0.85 loss in 2Q 2021)

Qlife Holding AB (publ) to Report Fiscal Year 2022 Results on Feb 16, 2023

High number of new and inexperienced directors

High number of new and inexperienced directors

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Jan Gorm Lisby First to Join Scientific Advisory Board

Qlife Develops New, Small, and Disposable Filtration Unit Able to Filtrate Plasma from Whole Blood

First quarter 2022 earnings released: kr0.99 loss per share (vs kr0.60 loss in 1Q 2021)

Full year 2021 earnings released: kr3.83 loss per share (vs kr1.92 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Qlife to Follow Up Danish Clinical Evaluation on Rapid Tests for Covid-19

High number of new and inexperienced directors

Independent Director recently bought kr116k worth of stock

Third quarter 2021 earnings released: kr0.97 loss per share (vs kr0.25 loss in 3Q 2020)

Independent Director Niklas Marschall has left the company

Independent Director Niklas Marschall has left the company

Second quarter 2021 earnings released

Is Qlife Holding (STO:QLIFE) A Risky Investment?

Independent Director exercised options to buy kr1.6m worth of stock.

Full year 2020 earnings released: kr1.92 loss per share (vs kr167 loss in FY 2019)

Is Qlife Holding (STO:QLIFE) A Risky Investment?

Qlife Holding AB (Publ) Announces CE Marks Its Covid-19 Test in the Egoo.Health System

New 90-day high: kr53.40

New 90-day high: kr45.55

New 90-day high: kr21.00

Qlife Holding AB (publ) Receives Order for Covid-19 Tests to European Women's Handball Championship 2020

Qlife Holding AB (publ) to Report Q2, 2020 Results on Aug 16, 2021

New 90-day low: kr15.76

Qlife Holding AB (publ) Provides Update on Application for Temporary Approval in Denmark

New 90-day high: kr20.80

New 90-day high - kr20.30

Qlife Holding AB (publ) to Report Fiscal Year 2021 Results on Feb 18, 2021

Analyse de la rémunération des PDG

PDG

Titularisation

Compensation

Membres du conseil d'administration

Durée moyenne de l'emploi

Âge moyen